Crohn's Disease Research Study
Researchers at the University of Michigan and partnering institutions are conducting a study on low-dose amitriptyline for abdominal pain or discomfort in adults with Crohn’s disease that is under control.
Fast Facts
Diagnosed with Crohn's Disease & have at least mild-moderate severity of abdominal pain
Crohn's Disease is currently under control
Compensation
provided up to $250
Conducted in
Ann Arbor, MI
Study Background
This clinical trial is studying whether low-dose amitriptyline can safely improve abdominal pain or discomfort in people with Crohn’s disease who are in remission.
Up to 40% of people with Crohn’s disease continue to experience ongoing abdominal pain and bowel changes even when their inflammation is under control. These symptoms can significantly impact daily life and overall quality of life. Currently, there are no evidence-based treatments specifically for patients with controlled Crohn’s disease who still experience these symptoms.
The AIMS-CD Trial (Amitriptyline for IBS-like Symptoms in Crohn’s Disease) is a study evaluating whether low-dose amitriptyline, a medication that may help reduce abdominal pain or discomfort, can improve symptoms in this population. Participants will receive either amitriptyline or a placebo for six months to assess tolerability, adherence, and symptom improvement.
Study Background
This clinical trial is studying whether low-dose amitriptyline can safely improve abdominal pain or discomfort in people with Crohn’s disease who are in remission.
Up to 40% of people with Crohn’s disease continue to experience ongoing abdominal pain and bowel changes even when their inflammation is under control. These symptoms can significantly impact daily life and overall quality of life. Currently, there are no evidence-based treatments specifically for patients with controlled Crohn’s disease who still experience these symptoms.
The AIMS-CD Trial (Amitriptyline for IBS-like Symptoms in Crohn’s Disease) is a study evaluating whether low-dose amitriptyline, a medication that may help reduce abdominal pain or discomfort, can improve symptoms in this population. Participants will receive either amitriptyline or a placebo for six months to assess tolerability, adherence, and symptom improvement.
Additional Information
This study aims to determine if a new medication may help reduce abdominal pain or discomfort.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Crohn’s disease that is under control
- Mild to moderate severity of abdominal pain or discomfort
- Stable IBD medications for at least the past 90 days
- No use of steroid medications for Crohn’s disease within the past 90 days
Complete a phone screening to determine eligibility
Attend a baseline in-person visit (Week 0)
Be randomized to receive either amitriptyline or placebo for 6 months
Attend virtual follow-up visits at Week 2 and Months 1, 3, and 6
Complete brief monthly online surveys to monitor safety and symptoms
Participants can receive up to $250 for completing the study.
There is no cost for you to participate in our research study.